# US 2017/0281697 A1 · Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281697 A1
- Document ID: US20170281697A1
- Status: Published application
- Kind: A1
- Application number: 15/083,570
- Filed: 2016-03-29
- Published: 2017-10-05
- Earliest claimed: 2016-03-29
- Assignees: Companion Supplements, LLC
- Applicants: Companion Supplements, LLC
- Inventors: Julio César Villamil Torres; Camilo Rey Ferro
- Web page: https://patentgrep.com/patent/US20170281697A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/295: Iron group metal compounds
- A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/08: Oxides; Hydroxides
- A61K 33/26: Iron; Compounds thereof
- A61K 35/745: Bifidobacteria
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
a) an absorption ready vitamin;
b) an absorption ready mineral;
c) a probiotic; and
d) a prebiotic; wherein the composition is formulated to prevent adverse effects associated with use of proton-pump inhibitors.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the vitamin is selected from the group consisting of vitamin D, vitamin K, and Vitamin B12.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein vitamin D is selected from the group consisting of calciferol, cholecalciferol, and ergocalciferol.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein the vitamin K is selected from the group comprising of menaquinone-7 and menaquinone-4.

### Claim 5 (depends on 2)

The pharmaceutical composition of claim 2, wherein the vitamin B12 is selected from the group comprising of methylcobalamin, cyanocobalamin and hydroxocobalamin.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the mineral is selected from the group consisting of a calcium salt, a magnesium salt, and an iron salt.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the calcium salt is selected from the group comprising of calcium citrate malate, calcium citrate, calcium carbonate, calcium ascorbate, calcium chelates or aminochelates, calcium gluconate, calcium malate, calcium glycinate, calcium aspartate, calcium succinate and calcium fumarate.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the magnesium salt is selected from the group comprising of magnesium oxide, magnesium citrate, magnesium malate, magnesium amino chelate, magnesium glycinate and magnesium carbonate.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6, wherein the iron salt is selected from the group comprising of ferrous bisglycinate, heme iron polypeptide, ferrous sulfate, ferrous fumarate, iron glycinate and iron pyrophosphate.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the probiotic is selected from the group comprising of Lactobacillus acidophilus, Lactobacillus casei, Bacillus clausi, Bacillus coagulans, Lactobacillus brevis, Lactobacillus vulgaricus, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus lactis, Lactobacillus reuteri, Bifidobacterium bifidum, Streptococcus thermophiles and Enterococcus faecium.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the probiotic comprises a mixture 50:50 comprising Lactobacillus acidophilus and Lactobacillus casei; and wherein the prebiotic comprises a mixture 50:50 comprising FOS (fructooligosaccharides) and inulin.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein:
a) a first vitamin is present in an amount of 5 μg to 25 μg, equivalent to 200 IU to 1,000 IU;
b) a second vitamin is present in an amount of 25 μg to 200 μg;
c) a third vitamin is present in an amount of 6 μg to 250 μg;
d) a calcium salt present in an amount of 837 mg to 4,183 mg, equivalent to 200 mg to 1,000 mg of elemental calcium;
e) a magnesium salt in an amount of 83 mg to 830 mg, equivalent to 50 mg to 500 mg of elemental magnesium;
f) an iron salt in an amount of 30 mg to 450 mg, equivalent to 6 mg to 90 mg of elemental iron;
g) a first probiotic in a concentration of 1 billion CFU to 10 billion CFU;
h) a second probiotic in a concentration of 1 billion CFU to 10 billion CFU;
i) a first prebiotic; and
j) a second prebiotic.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein:
a) the first vitamin is vitamin D3, as cholecalciferol, present in an amount of 10 μg to 20 μg, equivalent to 400 IU to 800 IU;
b) the second vitamin is vitamin K2, as menaquinone-7, present in an amount of 50 μg to 100 μg;
c) the third vitamin is vitamin B12, as methylcobalamin, in an amount of 50 μg to 100 μg;
d) calcium is present as calcium citrate malate, present in an amount of 1,046 mg to 2,092 mg, equivalent to 250 mg to 500 mg of elemental calcium;
e) magnesium is present as magnesium oxide, present in an amount of 166 mg to 664 mg, equivalent to 100 mg to 400 mg of elemental magnesium;
f) iron is present as ferrous bisglycinate, present in an amount of 90 mg to 225 mg, equivalent to 18 mg to 45 mg of elemental iron;
g) the first probiotic is Lactobacillus acidophilus, present in an amount of 2.5 billion CFU to 7.5 billion CFU;
h) the second probiotic is Lactobacillus casei, present in an amount of 2.5 billion CFU to 7.5 billion CFU;
i) the first prebiotic FOS (fructooligosaccharides), in an amount of 25 mg to 500 mg FOS (fructooligosaccharides), present in an amount of 50 mg to 200 mg; and
j) the second prebiotic is an inulin in an amount of between 25 mg to 500 mg.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, comprising an excipient.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the excipient is selected from the group consisting of a diluent, a disintegrant, a glidant, and a lubricant.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, further comprising:
a) a diluent in a concentration of 5% to 20% of the total weight of the preparation;
b) a disintegrant in a concentration of 0.5% to 5% of the total weight of the preparation;
c) a glidant in a concentration of 0.5% to 5% of the total weight of the preparation; and
d) a lubricant in a concentration of 0.5% to 3% of the total weight of the preparation.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1 used in a therapeutic treatment.

### Claim 18

A method of preparation of a pharmaceutical composition that prevents adverse effects associated with the use of proton-pump inhibitors, comprising:
a) sifting Vitamins D3, K2, and B12 and colloidal silicon dioxide through a #100 mesh;
b) geometrically diluting the vitamins D3, K2 and B12 in colloidal silicon dioxide and mixing for 5 minutes at each dilution;
c) sifting microcrystalline cellulose through a #30 mesh;
d) the geometric dilution of the pre-mix obtained in step b) in microcrystalline cellulose is carried out, mixing for 5 minutes at each dilution;
e) separately, Lactobacillus acidophilus, Lactobacillus casei, FOS (fructooligosaccharides), and inulin are mixed for 5 minutes after being previously sifted through a #30 mesh;
f) separately, iron bisglycinate, magnesium oxide, and sodium croscarmellose are mixed for 5 minutes after being previously sifted through a #30 mesh;
g) calcium citrate malate is placed in a “V” mixer after being previously sifted through a #20 mesh;
h) the pre-mix obtained in step d) is added to the mixer and mixed for 10 minutes;
i) the pre-mix obtained in step e) is added to the mixer and mixed for 10 minutes;
j) the pre-mix obtained in step f) is added to the mixer and mixed for 10 minutes;
k) the vegetable magnesium stearate, previously sifted through a #60 mesh, is added to the mixer and mixed for 3 minutes; and
l) a “#00” capsule is filled to obtain an average weight of 850 mg per capsule.

### Claim 19

A method of treatment to avoid adverse effects associated with the use of proton-pump inhibitors, comprising:
oral administration of cholecalciferol from 10 μg and 20 μg, equivalent to 400 IU and 800 IU of vitamin D3; menaquinone-7 from 50 μg to 100 μg; methylcobalamin from 50 μg to 100 μg; calcium citrate malate from 1,046 mg to 2,092 mg, equivalent to 250 mg to 500 mg of elemental calcium; magnesium oxide from 166 mg to 664 mg, equivalent to 100 mg to 400 mg of elemental magnesium; ferrous bisglycinate from 90 mg to 225 mg, equivalent to 18 mg to 45 mg of elemental iron; Lactobacillus acidophilus from 2.5 billion CFU to 7.5 billion CFU; Lactobacillus casei from 2.5 billion CFU to 7.5 billion CFU; FOS (fructooligosaccharides) from 50 mg to 200 mg; and inulin from 50 mg to 200 mg.

### Claim 20 (depends on 19)

The method of treatment of claim 19, wherein the oral administration is given from 4 to 6 hours after the first daily administration of the proton-pump inhibitor by using two capsules or tablets, each one containing half the total daily dose required.
